Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

Stock Information for Entero Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Entero Therapeutics Inc.

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Entero Therapeutics Appoints Richard Paolone as CEO
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SUM, STAF, ALVR, ENTO on Behalf of Shareholders
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of SUM, ENTO, ALVR and STAF
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBRDA, SUM, MNTX, ENTO on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.